Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model

Jean L. Grem, Jacqueline Plowman, Larry Rubinstein, Michael J. Hawkins, Steadman D. Harrison

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

3-Deazauridine (DAUrd), a competitive inhibitor of CTP synthetase, inhibits both RNA and DNA synthesis. Murine leukemia cells resistant to cytosine arabinoside (ara-C) due to a deletion of deoxycytidine kinase are collaterally sensitive to DAUrd, which inhibits the de novo production of CTP and hence results in dCTP depletion. We evaluated DAUrd in combination with the palmitate derivative of ara-C (palmO-ara-C) in mice bearing L1210 leukemia cells with a subpopulation resistant to ara-C. Both simultaneous administration and a sequential schedule of palmO-ara-C at its maximally tolerated dose (MTD), followed by DAUrd treatment, failed to produce a therapeutic gain. We also studied whether non-toxic doses of DAUrd (15-250 mg/kg i.p. at h 0 and 6 on days 4 and 8) could modulate the antileukemic activity of palmO-ara-C (7.5-120 mg/kg i.p. at h 3 on days 4 and 8). The addition of DAUrd produced a modest (but statistically significant) prolongation of life span and a further 2-log10 reduction in tumor burden compared to the same dose of palmO-ara-C alone, and resulted in long-term survivors in five of 30 treated animals. Two-dimensional dose-response analysis of the survival data indicated a positive drug interaction (p {slanted equal to or less-than} 0.01) when the dosage of DAUrd was modeled to reflect an apparent threshold effect. Cyclopentenyl cytosine (CPE-C; 0.625-2.5 mg/kg i.p. at h 0 and 6 on days 4 and 8), a more potent inhibitor of CTP synthetase, was also given with palmO-ara-C. This combination resulted in an additional 2-6log10 units of cell kill and occasional long-term survivors at palmO-ara-C dosages that alone resulted in no more than 2log10 units of cell kill and no long-term survivors. However, DAUrd and CPE-C given with palmO-ara-C increased host toxicity, compromising the tolerable dose of palmO-ara-C. Single-agent palmO-ara-C given at its MTD produced a similar reduction in tumor burden and increase in life span compared to the highest palmO-ara-C dose that could be given in combination with either modulator.

Original languageEnglish (US)
Pages (from-to)229-236
Number of pages8
JournalLeukemia Research
Volume15
Issue number4
DOIs
StatePublished - 1991

Fingerprint

3-Deazauridine
Cytarabine
Palmitates
Leukemia
CTP synthetase
Survivors
Maximum Tolerated Dose
cyclopentenyl cytosine
Tumor Burden
Deoxycytidine Kinase
Life Support Care
Cytidine Triphosphate
Leukemia L1210
Survival Analysis

Keywords

  • 3-deazauridine
  • ara-C
  • leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model. / Grem, Jean L.; Plowman, Jacqueline; Rubinstein, Larry; Hawkins, Michael J.; Harrison, Steadman D.

In: Leukemia Research, Vol. 15, No. 4, 1991, p. 229-236.

Research output: Contribution to journalReview article

Grem, Jean L. ; Plowman, Jacqueline ; Rubinstein, Larry ; Hawkins, Michael J. ; Harrison, Steadman D. / Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model. In: Leukemia Research. 1991 ; Vol. 15, No. 4. pp. 229-236.
@article{b66e6c70987940c4bd4d08c9b46454b0,
title = "Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model",
abstract = "3-Deazauridine (DAUrd), a competitive inhibitor of CTP synthetase, inhibits both RNA and DNA synthesis. Murine leukemia cells resistant to cytosine arabinoside (ara-C) due to a deletion of deoxycytidine kinase are collaterally sensitive to DAUrd, which inhibits the de novo production of CTP and hence results in dCTP depletion. We evaluated DAUrd in combination with the palmitate derivative of ara-C (palmO-ara-C) in mice bearing L1210 leukemia cells with a subpopulation resistant to ara-C. Both simultaneous administration and a sequential schedule of palmO-ara-C at its maximally tolerated dose (MTD), followed by DAUrd treatment, failed to produce a therapeutic gain. We also studied whether non-toxic doses of DAUrd (15-250 mg/kg i.p. at h 0 and 6 on days 4 and 8) could modulate the antileukemic activity of palmO-ara-C (7.5-120 mg/kg i.p. at h 3 on days 4 and 8). The addition of DAUrd produced a modest (but statistically significant) prolongation of life span and a further 2-log10 reduction in tumor burden compared to the same dose of palmO-ara-C alone, and resulted in long-term survivors in five of 30 treated animals. Two-dimensional dose-response analysis of the survival data indicated a positive drug interaction (p {slanted equal to or less-than} 0.01) when the dosage of DAUrd was modeled to reflect an apparent threshold effect. Cyclopentenyl cytosine (CPE-C; 0.625-2.5 mg/kg i.p. at h 0 and 6 on days 4 and 8), a more potent inhibitor of CTP synthetase, was also given with palmO-ara-C. This combination resulted in an additional 2-6log10 units of cell kill and occasional long-term survivors at palmO-ara-C dosages that alone resulted in no more than 2log10 units of cell kill and no long-term survivors. However, DAUrd and CPE-C given with palmO-ara-C increased host toxicity, compromising the tolerable dose of palmO-ara-C. Single-agent palmO-ara-C given at its MTD produced a similar reduction in tumor burden and increase in life span compared to the highest palmO-ara-C dose that could be given in combination with either modulator.",
keywords = "3-deazauridine, ara-C, leukemia",
author = "Grem, {Jean L.} and Jacqueline Plowman and Larry Rubinstein and Hawkins, {Michael J.} and Harrison, {Steadman D.}",
year = "1991",
doi = "10.1016/0145-2126(91)90125-D",
language = "English (US)",
volume = "15",
pages = "229--236",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model

AU - Grem, Jean L.

AU - Plowman, Jacqueline

AU - Rubinstein, Larry

AU - Hawkins, Michael J.

AU - Harrison, Steadman D.

PY - 1991

Y1 - 1991

N2 - 3-Deazauridine (DAUrd), a competitive inhibitor of CTP synthetase, inhibits both RNA and DNA synthesis. Murine leukemia cells resistant to cytosine arabinoside (ara-C) due to a deletion of deoxycytidine kinase are collaterally sensitive to DAUrd, which inhibits the de novo production of CTP and hence results in dCTP depletion. We evaluated DAUrd in combination with the palmitate derivative of ara-C (palmO-ara-C) in mice bearing L1210 leukemia cells with a subpopulation resistant to ara-C. Both simultaneous administration and a sequential schedule of palmO-ara-C at its maximally tolerated dose (MTD), followed by DAUrd treatment, failed to produce a therapeutic gain. We also studied whether non-toxic doses of DAUrd (15-250 mg/kg i.p. at h 0 and 6 on days 4 and 8) could modulate the antileukemic activity of palmO-ara-C (7.5-120 mg/kg i.p. at h 3 on days 4 and 8). The addition of DAUrd produced a modest (but statistically significant) prolongation of life span and a further 2-log10 reduction in tumor burden compared to the same dose of palmO-ara-C alone, and resulted in long-term survivors in five of 30 treated animals. Two-dimensional dose-response analysis of the survival data indicated a positive drug interaction (p {slanted equal to or less-than} 0.01) when the dosage of DAUrd was modeled to reflect an apparent threshold effect. Cyclopentenyl cytosine (CPE-C; 0.625-2.5 mg/kg i.p. at h 0 and 6 on days 4 and 8), a more potent inhibitor of CTP synthetase, was also given with palmO-ara-C. This combination resulted in an additional 2-6log10 units of cell kill and occasional long-term survivors at palmO-ara-C dosages that alone resulted in no more than 2log10 units of cell kill and no long-term survivors. However, DAUrd and CPE-C given with palmO-ara-C increased host toxicity, compromising the tolerable dose of palmO-ara-C. Single-agent palmO-ara-C given at its MTD produced a similar reduction in tumor burden and increase in life span compared to the highest palmO-ara-C dose that could be given in combination with either modulator.

AB - 3-Deazauridine (DAUrd), a competitive inhibitor of CTP synthetase, inhibits both RNA and DNA synthesis. Murine leukemia cells resistant to cytosine arabinoside (ara-C) due to a deletion of deoxycytidine kinase are collaterally sensitive to DAUrd, which inhibits the de novo production of CTP and hence results in dCTP depletion. We evaluated DAUrd in combination with the palmitate derivative of ara-C (palmO-ara-C) in mice bearing L1210 leukemia cells with a subpopulation resistant to ara-C. Both simultaneous administration and a sequential schedule of palmO-ara-C at its maximally tolerated dose (MTD), followed by DAUrd treatment, failed to produce a therapeutic gain. We also studied whether non-toxic doses of DAUrd (15-250 mg/kg i.p. at h 0 and 6 on days 4 and 8) could modulate the antileukemic activity of palmO-ara-C (7.5-120 mg/kg i.p. at h 3 on days 4 and 8). The addition of DAUrd produced a modest (but statistically significant) prolongation of life span and a further 2-log10 reduction in tumor burden compared to the same dose of palmO-ara-C alone, and resulted in long-term survivors in five of 30 treated animals. Two-dimensional dose-response analysis of the survival data indicated a positive drug interaction (p {slanted equal to or less-than} 0.01) when the dosage of DAUrd was modeled to reflect an apparent threshold effect. Cyclopentenyl cytosine (CPE-C; 0.625-2.5 mg/kg i.p. at h 0 and 6 on days 4 and 8), a more potent inhibitor of CTP synthetase, was also given with palmO-ara-C. This combination resulted in an additional 2-6log10 units of cell kill and occasional long-term survivors at palmO-ara-C dosages that alone resulted in no more than 2log10 units of cell kill and no long-term survivors. However, DAUrd and CPE-C given with palmO-ara-C increased host toxicity, compromising the tolerable dose of palmO-ara-C. Single-agent palmO-ara-C given at its MTD produced a similar reduction in tumor burden and increase in life span compared to the highest palmO-ara-C dose that could be given in combination with either modulator.

KW - 3-deazauridine

KW - ara-C

KW - leukemia

UR - http://www.scopus.com/inward/record.url?scp=0025843593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025843593&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(91)90125-D

DO - 10.1016/0145-2126(91)90125-D

M3 - Review article

C2 - 2030604

AN - SCOPUS:0025843593

VL - 15

SP - 229

EP - 236

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -